跳至主要内容
临床试验/NCT01361087
NCT01361087撤回3 期

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With

Ann & Robert H Lurie Children's Hospital of Chicago2 个研究点 分布在 1 个国家开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
试验地点
2
主要终点
To determine if circulating levels of TGF-β correlate with treatment arms: Atenolol vs. Losartan.

研究概览

简要总结

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice.

详细描述

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice. This suggest that while the symptoms of Marfan syndrome may seem consistent with a connective tissue disorder, the mechanism is more likely related to reduced sequestration of TGF-β by fibrillin.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
6 Months 至 24 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Individual with Marfan syndrome consented in to the Main Atenolol Vs. Losartan NIH study.

排除标准

  • Subjects in the main PHN Marfan trial who have not achieved the maintenance drug dosing or who have stopped taking study drug.

结局指标

主要结局

To determine if circulating levels of TGF-β correlate with treatment arms: Atenolol vs. Losartan.

时间窗: 1 year

次要结局

  • To determine if circulating levels of TGF-β correlate with clinical outcomes within a treatment group or independent treatment groups.(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验